Guanylate cyclase-C agonist on intestinal epithelium; elevates intracellular cGMP, opening CFTR and increasing chloride / fluid secretion into the gut lumen.
Reference facts
- Also known as
- Linzess, Constella
- Category
- Gastrointestinal
- Mechanism of action
- Guanylate cyclase-C agonist on intestinal epithelium; elevates intracellular cGMP, opening CFTR and increasing chloride / fluid secretion into the gut lumen.
- Targets
- GC-C receptor
- Indications under research or approved
- Chronic idiopathic constipation, IBS-C, Functional constipation in pediatrics
- Regulatory status (reference entry)
- FDA-approved (2012)
- Half-life
- Negligible systemic absorption
- Sequence
- CCEYCCNPACTGCY
- Sequence notes
- 14-residue cyclic peptide with three disulfide bonds; oral, gut-restricted.
- Molecular weight (Da)
- 1527
- Originator / sponsor
- Ironwood / AbbVie
- First reported
- 2008
Primary References
Explore research articles about Linaclotide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.